Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of a primary care intervention on diabetes distress in individuals with newly diagnosed type 2 diabetes: a cluster-randomized controlled trial.

BMC primary care·2026
Same author

Conceptualizing culture change as an impact metric. A scoping review and abductive thematic analysis of culture-related outcomes from patient and public involvement in healthcare and health research.

Research involvement and engagement·2025
Same author

Patient experiences with group consultations when treated with semaglutide for obesity: a qualitative case study in a Danish general practice.

BMJ open·2025
Same author

NaF-PET/CT imaging of atherosclerosis in type 2 diabetes: Associations with sex and history of cardiovascular events in a 2-year follow-up study.

European journal of nuclear medicine and molecular imaging·2025
Same author

Educational inequalities in clinical presentation and pharmacological treatment of early type 2 diabetes: A Danish prevalence study.

Diabetes research and clinical practice·2025
Same author

Diabetes and vulnerabilities in people undergoing lower-extremity amputation.

Danish medical journal·2025

Related Experiment Video

Updated: May 18, 2026

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

[Type 2 diabetes in Denmark].

Henning Beck-Nielsen1, Jan Erik Henriksen

  • 1Endokrinologisk Afdeling M, Odense Universitetshospital, Kløvervænget 6, 5000 Odense C, Denmark. Henning.beck-nielsen@ouh.regionsyddanmark.dk

Ugeskrift for Laeger
|September 14, 2012
PubMed
Summary
This summary is machine-generated.

This study proposes improving opportunistic screening to detect hidden type 2 diabetes (T2D) early. Personalized treatment goals and reduced polypharmacy are key for better patient outcomes in T2D management.

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Related Experiment Videos

Last Updated: May 18, 2026

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Public Health

Context:

  • Type 2 Diabetes (T2D) diagnosis and management present challenges.
  • Opportunistic screening can identify undiagnosed cases.
  • Current management may lead to polypharmacy and suboptimal outcomes.

Purpose:

  • To enhance opportunistic screening for occult type 2 diabetes.
  • To establish personalized treatment goals for HbA1c, blood pressure, and lipids.
  • To optimize pharmacotherapy by aligning drug regimens with patient phenotypes and reducing polypharmacy.

Summary:

  • A new organizational flowchart for T2D management is proposed.
  • General practitioners are designated as co-ordinators for T2D care.
  • The system aims for early detection and tailored treatment to prevent complications and polypharmacy.

Impact:

  • Improved early detection of type 2 diabetes.
  • Reduced polypharmacy and associated risks.
  • Enhanced patient care through phenotyping and personalized goals.